GV.PA Genomic Vision SA EURONEXT pre-market 15 Jan 2026: 38.49M shares at €0.0018, watch liquidity
GV.PA stock is the most active name in pre-market trading on EURONEXT on 15 Jan 2026, with 38.49M shares changing hands and a quoted price of €0.0018. Volume today is about 2.71x the average, pushing liquidity to the top of traders’ watch lists. Intraday range sits near €0.0015–€0.0020, while the company remains a micro-cap in the Healthcare diagnostics sector. We examine trading drivers, valuation, balance sheet metrics and a model forecast to frame risk and opportunity for short-term and strategic investors.
Pre-market snapshot: GV.PA stock momentum
GV.PA stock opened pre-market at €0.0018, up 5.88% from the previous close of €0.0017. Reported volume is 38.49M versus an average of 14.22M, a relative volume of 2.71, signalling outsized interest in early trading.
Intraday liquidity is concentrated between the day low €0.0015 and day high €0.0020. For most-active traders, tight execution and spread risk matter more than fundamentals at this price scale.
Balance sheet and valuation: GV.PA analysis
Genomic Vision SA (GV.PA) shows a market cap of €693,191.00 and shares outstanding of 385,105,984. Key ratios flag stress: EPS -0.11, P/E negative, price to sales 0.47, and book value per share -0.01 indicating negative equity on a per-share basis.
Current ratio is 0.91 and cash per share is €0.00557, highlighting limited short-term buffers. Enterprise value of €2,369,191.00 versus sales gives an EV/sales of 1.60, but negative margins and high days inventory raise valuation risk for buy-and-hold investors.
Trading activity, technicals and most-active context for GV.PA stock
The stock’s 50-day average price is €0.00484 and 200-day average is €0.01399, both well above the current quote, underscoring a prolonged downtrend. Price fell roughly 96.91% over the last year from the peak, per the supplied change metrics.
High turnover today can amplify volatility: a small block trade will move price materially. For active traders, watch market depth, bid-ask spread and whether institutional-sized orders appear.
Operational outlook and sector context: GV.PA news and developments
Genomic Vision SA operates in Healthcare, Medical – Diagnostics & Research, offering the FiberVision molecular combing platform and related reagents and services. The company lists partnerships with Quest Diagnostics and research ties to Institut Pasteur and La Timone Hospital, which support commercial validation and R&D pipelines.
Sector peers in Healthcare trade with stronger margins and higher ROCE; the sector average ROCE is 8.73%, so Genomic Vision’s negative profitability places it below peers, increasing execution risk despite niche technology.
Meyka AI grade & forecast for GV.PA stock
Meyka AI rates GV.PA with a score out of 100: 58.71 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry comparison, financial growth, key metrics, forecasts, analyst consensus and fundamental growth.
Meyka AI’s forecast model projects a 12-month target of €0.0100 versus the current price €0.0018, implying an upside of 455.56%. Forecasts are model-based projections and not guarantees. Investors should weigh model upside against severe liquidity, negative profitability and capital structure constraints.
Final Thoughts
Key takeaways for GV.PA stock: pre-market activity on EURONEXT on 15 Jan 2026 is dominated by heavy volume ( 38.49M shares) at a quoted price of €0.0018, driving short-term liquidity and volatility. Financials show negative EPS (-0.11), book value per share below zero and a current ratio of 0.91, which increase solvency risk for long-term holders. Trading metrics underline the stock’s speculative nature: 50-day average €0.00484, 200-day average €0.01399, and a year high of €0.094 compared to today’s quote. Meyka AI’s forecast model projects €0.0100 at 12 months, implying 455.56% upside from €0.0018, but this is balanced by operational and liquidity risks. Use tight risk controls, monitor depth and news flows, and treat GV.PA as a high-volatility micro-cap. Meyka AI, our AI-powered market analysis platform, highlights the trade-off between large model upside and significant execution risk. For additional reading on market conditions and biotech sector flows see Reuters and longer market commentary at Seeking Alpha.
FAQs
What is driving the pre-market volume spike in GV.PA stock?
Pre-market volume for GV.PA stock rose due to short-term liquidity trades and heightened interest from active traders. Reported volume is 38.49M, about 2.71x the average, which typically reflects speculative flows, news scans or block orders rather than improved fundamentals.
How does Meyka AI view GV.PA stock and its forecast?
Meyka AI rates GV.PA with a score out of 100 at 58.71 (Grade C+, Suggestion: HOLD). Meyka AI’s forecast model projects €0.0100 in 12 months versus current €0.0018. Forecasts are model-based projections and not guarantees.
What are the main financial risks for investors in GV.PA stock?
Major risks include negative EPS (-0.11), negative book value per share, limited cash per share (€0.00557), and a current ratio below 1.0. These metrics indicate potential funding pressure and high dilution or restructuring risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
